Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time-to-meet decline

✍ Scribed by Black, Sandra; Bakchine, Serge; Bellelli, Giuseppe; Molinuevo, Jose Luis; Downs, Pamela; Caputo, Angelika; Strohmaier, Christine

• Book ID: 122629489
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 82 KB
• Volume: 8
• Category: Article
• ISSN: 1552-5260
• DOI: 10.1016/j.jalz.2012.05.2097